These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21659409)

  • 1. Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3.
    Borget I; Cadranel J; Pignon JP; Quoix E; Coudert B; Westeel V; Dansin E; Madelaine J; Madroszyk A; Friard S; Daniel C; Morin F; Chouaid C;
    Eur Respir J; 2012 Jan; 39(1):172-9. PubMed ID: 21659409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
    Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
    J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.
    Ting J; Tien Ho P; Xiang P; Sugay A; Abdel-Sattar M; Wilson L
    Value Health; 2015 Sep; 18(6):774-82. PubMed ID: 26409604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib for the treatment of relapsed non-small cell lung cancer.
    McLeod C; Bagust A; Boland A; Hockenhull J; Dundar Y; Proudlove C; Davis H; Green J; Macbeth F; Stevenson J; Walley T; Dickson R
    Health Technol Assess; 2009 Jun; 13 Suppl 1():41-7. PubMed ID: 19567213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).
    Chouaid C; Le Caer H; Corre R; Crequit J; Locher C; Falchero L; Dujon C; Berard H; Monnet I; Vergnenegre A
    Clin Lung Cancer; 2013 Mar; 14(2):103-7. PubMed ID: 22682669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
    Lee VW; Schwander B; Lee VH
    Hong Kong Med J; 2014 Jun; 20(3):178-86. PubMed ID: 24281768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and economic review of erlotinib in non-small-cell lung cancer.
    Yeung K; Carlson JJ
    Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):411-23. PubMed ID: 22971028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
    Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
    Narita Y; Matsushima Y; Shiroiwa T; Chiba K; Nakanishi Y; Kurokawa T; Urushihara H
    Lung Cancer; 2015 Oct; 90(1):71-7. PubMed ID: 26259876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
    Pallis AG; Voutsina A; Kentepozidis N; Giassas S; Papakotoulas P; Agelaki S; Tryfonidis K; Kotsakis A; Vamvakas L; Vardakis N; Georgoulias V
    Clin Lung Cancer; 2012 Mar; 13(2):129-35. PubMed ID: 22000696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.
    Carlson JJ; Garrison LP; Ramsey SD; Veenstra DL
    Value Health; 2009; 12(1):20-7. PubMed ID: 18647257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erlotinib or docetaxel for second-line treatment of non-small cell lung cancer: a real-world cost-effectiveness analysis.
    Cromwell I; van der Hoek K; Melosky B; Peacock S
    J Thorac Oncol; 2011 Dec; 6(12):2097-103. PubMed ID: 22052223
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom.
    Lewis G; Peake M; Aultman R; Gyldmark M; Morlotti L; Creeden J; de la Orden M
    J Int Med Res; 2010; 38(1):9-21. PubMed ID: 20233509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.
    Salazar F; Molina MA; Sanchez-Ronco M; Moran T; Ramirez JL; Sanchez JM; Stahel R; Garrido P; Cobo M; Isla D; Bertran-Alamillo J; Massuti B; Cardenal F; Manegold C; Lianes P; Trigo JM; Sanchez JJ; Taron M; Rosell R
    Lung Cancer; 2011 Apr; 72(1):84-91. PubMed ID: 20705357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
    Thongprasert S; Tinmanee S; Permsuwan U
    Asia Pac J Clin Oncol; 2012 Mar; 8(1):53-61. PubMed ID: 22369444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
    Krawczyk P; Kowalski DM; Wojas-Krawczyk K; Mlak R; Jaśkiewicz P; Kucharczyk T; Winiarczyk K; Krzakowski M; Milanowski J
    Chemotherapy; 2012; 58(1):60-9. PubMed ID: 22338650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
    Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
    Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
    Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.